share_log

10月12日明德生物涨停分析:医疗器械,体外诊断,新冠检测概念热股

Mingde Biological limit Analysis on Oct. 12: medical Devices, in Vitro diagnosis, COVID-19 Detection Conceptual Hot stocks

證券之星 ·  Oct 12, 2021 03:10

Securities Star data center news, Mingde biological trading closed, closing price 68.37 yuan. The stock rose by the limit at 09:31, opened the limit twice, and closed with a capital of 57.7677 million yuan, accounting for 1.41% of its current market value.

In terms of capital flow data, the net inflow of main funds on the same day was 78.0054 million yuan, the net inflow of hot capital was 91.9048 million yuan, and the net outflow of retail funds was 41.1289 million yuan. The flow of funds in the past five days is shown in the following table:

This unit is a concept hot unit for medical devices, in vitro diagnosis and COVID-19 testing.

The investment logic of the stock is as follows:

1. One of the main suppliers in the field of in vitro diagnostic POCT in China. The company's main products include POCT rapid diagnostic reagents and rapid detection instruments, in which rapid diagnostic reagents are divided into infectious disease series, cardiovascular and cerebrovascular disease series, kidney disease series, diabetes series, obstetrics and gynecology eugenics series, health examination series and so on. Instruments include immune quantitative analyzer, mobile electrocardiograph, glycosylated hemoglobin analyzer, etc. In 1919, the income of rapid diagnostic reagents was 162 million yuan, accounting for 89.25%, and that of rapid diagnostic instruments was 4.492 million yuan, accounting for 2.48%.

2. Disclosed in April 20, the company novel coronavirus 2019-nCoV nucleic acid detection kit (fluorescent PCR method) was intended to be selected for the centralized procurement of novel coronavirus related testing reagents in Hubei Province; in May 21, it was disclosed that novel coronavirus (2019-nCoV) antigen detection kit (colloidal gold method) (COVID-19 (SARS-CoV-2) Antigen Test Kit) self-test type is still registered.

From the perspective of financial situation, the Mingde Biological 2021 report showed that the company's main income was 1.141 billion yuan, up 216.54% from the same period last year; the net profit from its parent was 580 million yuan, up 189.53% from the same period last year; deducting 577 million yuan from non-net profit, up 187.2% from the same period last year; debt ratio 12.62%, investment income 103000 yuan, financial expenses-1.8264 million yuan, gross profit margin 76.36%.

Securities Star valuation analysis tool shows that the stock has a good company rating of 3.5 stars, a good price rating of 3 stars, and a comprehensive valuation rating of 3 stars.

Disclaimer: the relevant content according to the public big data analysis, does not constitute investment advice, the stock market is risky, investment should be cautious.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment